ADC Therapeutics SA (ADCT) vs Journey Medical (DERM)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Journey Medical (DERM) has outperformed ADC Therapeutics SA (ADCT) over the past year, losing 21.2% versus a loss of 67.1%. ADC Therapeutics SA is the larger company by market cap ($206.8 million vs $170.8 million), about 1.2 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ADCT | DERM |
|---|---|---|
| Share price | $1.62 | $6.05 |
| Market cap | $206.82M | $170.76M |
| 1-day change | +14.08% | +1.68% |
| YTD return | -59.77% | -22.83% |
| 1-year return | -67.05% | -21.19% |
| 5-year return | -94.42% | — |
| EPS (TTM) | $-0.60 | $-0.22 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $4.98 | $9.56 |
| 52-week low | $0.78 | $4.31 |
| Distance from 52-week high | -67.47% | -36.68% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +105.56% | +127.27% |
| Average volume | 1.35M | 182.16K |
| Shares outstanding | 127.67M | 22.22M |
| Employees | 188 | 58 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- DERM has outperformed ADCT by 45.9 percentage points over the past year.
About ADC Therapeutics SA
ADCT stock →ADC Therapeutics SA provides antibody drug conjugate (ADC) technology platform in Switzerland and the United States. Its flagship product includes ZYNLONTA, a CD19-directed ADC, received accelerated approval from the U.S.
Health Care · Biotechnology: Pharmaceutical Preparations · 188 employees
About Journey Medical
DERM stock →Journey Medical Corporation, a commercial-stage pharmaceutical company that focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's marketed products include Qbrexza, a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug to treat severe recalcitrant nodular acne; and Amzeeq, a topical formulation of minocycline for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris.
Health Care · Biotechnology: Pharmaceutical Preparations · 58 employees
ADCT vs DERM FAQ
Which is bigger, ADC Therapeutics SA or Journey Medical?
ADC Therapeutics SA (ADCT) is larger, with a market capitalization of $206.82M compared with $170.76M for Journey Medical (DERM).
Which stock has performed better over the past year, ADCT or DERM?
DERM returned -21.19% over the past 12 months, compared with -67.05% for ADCT (price return, excluding dividends). Past performance does not predict future results.
Are ADC Therapeutics SA and Journey Medical in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.